Ensysce Biosciences

More great progress with our first ever Overdose protection program, PF614-MPAR. accessnewswire.com/newsroom/en/he…

Opioid Use Disorder (OUD) is a crippling illness that ruins the quality of life for sufferers. Around 4% of adults in the USA (~10 million) need treatment, but only 25% of that number receive it*. Ensysce have a novel therapy in development. *Ref. CDC #OUD #Methadone

Chronic pain after affects between 10 and 50% of the population after surgery at some point in their lives. Post-surgical pain is a key target for PF614 from Ensysce, and we believe our unique profile will bring real benefits. #surgery #severepain #TAAP

$ENSC @EnsysceBio is Moving Closer to Changing the Pain Relief Market buff.ly/NbtyA8M

Lynn Kirkpatrick, Ensysce CEO, visited the NYSE recently to discuss TAAP and MPAR. Pictured here with Dr Neil Pathak from Creighton University and Jane King, host of Today’s marketplace. #NYSE #TAAP #MPAR

The Ensysce Team will be attending the 37th Annual Roth Conference in LA. accessnewswire.com/newsroom/en/he… #TAAP #Pain #Roth

Pain treatment is affected by where you live. A recent CDC study found that people in non-metropolitan areas are 50% more likely to suffer from chronic pain than those in large population centers. This may be due to access to healthcare. #pain #health

Women in Pain 25% of women experience chronic pain in any given year, and almost 10% have high impact chronic pain. Ensysce is focused on helping these people with safer solutions. #pain #TAAP #HICP

International Day of Women in Science The majority of the Ensysce team, including our CEO, are women. Today we celebrate all the women who drive science forward and bring help to those with serious illnesses. #womensday #pain #reseach

World Cancer Day There are around 20 million new cases of cancer per year. As cancer treatments improve, we at Ensysce believe there is a need for safer ways to treat cancer pain. Ensysce believes PF614 has a key role in treating cancer pain. #cancer #pain #TAAP

The Ensysce team has a dream of reducing severe pain. We are one step closer in 2025 as our Phase 3 trial will begin. #dream #pain #MPAR

‘Make your dreams come true day’. Anyone who has suffered with chronic and/or severe pain wishes for a safe solution. The Ensysce team is committed to delivering one. #painfree #TAAP

Happy New Year for 2025. We hope this year is joyful, productive and pain free. Our team has made several resolutions, the most important being to help people with severe pain. #NY2025 #TAAP #pain

Ensysce Biosciences wishes you a very Happy Holiday Season, one that is pain free and filled with good health and happiness. ensysce.com #Holidayseason #painmanagement #nextgenpharma

Happy National Bill of Rights Day! An important day to celebrate America’s Constitution granting freedom of speech, press and religion. At Ensysce, we want to celebrate freedom from pain. archives.gov/news/topics/bi… #nationalbillofrightsday #billofrightsday #patientsrights

Human Rights Day We celebrate this important day and believe that life without pain should be a human right. We have a mission to reduce pain. #ensysce #painfree #painfreedom

Patients in pain achieve an average of only 30% pain reduction from their treatment. Opioids are now under-used due to prescribing restrictions. We need safer opioids. #opioids #TAAP #pain

Important update for Ensysce. We are entering an exclusive supply chain agreement with a specialty pharma company. One step closer to commercialization. #galephar #TAAP #pain accesswire.com/950104/ensysce…

Chronic pain affects nearly one in four U.S. adults. In 2023, 24.3% of adults had chronic pain lasting 3 months or longer, reported by the CDC's National Center for Health Statistics (NCHS). Ensysce has a plan to impact these figures. #TAAP #opioids #pain

8% of Americans are suffering from high impact chronic pain (HICP); that’s over 26 million people in severe pain. Ensysce is working to launch effective yet safer options for those in need. #nomorepain #pain #HICP